Octopharma has initiated a Phase II/III Study of its intravenous immunoglobulin preparation (IVIG) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
The study will be randomised, double-blind, placebo-controlled, adaptive and multi-centre, and will evaluate the safety and efficacy of Octapharma’s 10% novel intravenous immunoglobulin for CIDP treatment.
Go deeper with GlobalData
The results will be used to support the regulatory filing of IVIG in Europe and the US.
CIDP is a neurological disorder characterised by impaired sensation, areflexia, and slow onset of weakness.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
